ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV.

By P. Ferenci, D. Bernstein, J. Lalezari, D. Cohen, Yan Luo, C. Cooper, E. Tam, R. Marinho, N. Tsai, A. Nyberg and 19 more. New England Journal of Medicine, 2014

772 citations recorded by the source corpus.

Subfields: Hematology, Hepatology, Infectious Diseases

View Paper: https://www.semanticscholar.org/paper/014c0888c25cea7a605d10b2202a332c80e914e2

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Hepatology

1. Christoph Sarrazin
2. A. Aghemo
3. G. Dusheiko
4. M. Puoti
5. X. Forns
6. J. Pawlotsky

Citations in the corpus

• EASL Recommendations on Treatment of Hepatitis C 2018. (2018, neutral): “In the PEARL-3 trial, the SVR12 rate was 99% (207/209) in treatment-naïve patients without cirrhosis infected with subtype 1b receiving the triple combination of ritonavir-boosted paritaprevir, ombitasvir and dasabuvir for 12 weeks.(89) In MALACHITE-1, the SVR12 rate in treatment-naïve patients with”
• EASL Recommendations on Treatment of Hepatitis C 2015. (2015, background): “In PEARL-III, the SVR12 rates were 99% (207/209) and 99% (209/210) without and with ribavirin, respectively, in treatment-naïve non-cirrhotic patients infected with subtype 1b [41].”